Liberty Capital Management Inc. grew its stake in Stryker Corporation (NYSE:SYK) by 43.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,091 shares of the medical technology company’s stock after purchasing an additional 1,541 shares during the quarter. Liberty Capital Management Inc.’s holdings in Stryker were worth $806,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of SYK. Acrospire Investment Management LLC acquired a new stake in Stryker during the second quarter worth about $111,000. Motco raised its stake in Stryker by 50.7% during the second quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 278 shares during the period. Sawyer & Company Inc acquired a new stake in Stryker during the fourth quarter worth about $125,000. Sit Investment Associates Inc. raised its stake in Stryker by 114.3% during the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 440 shares during the period. Finally, San Francisco Sentry Investment Group CA raised its stake in Stryker by 47.8% during the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 325 shares during the period. Institutional investors and hedge funds own 74.88% of the company’s stock.

Shares of Stryker Corporation (NYSE SYK) traded down $0.37 during trading hours on Tuesday, hitting $158.23. 1,138,900 shares of the company’s stock traded hands, compared to its average volume of 1,207,278. Stryker Corporation has a 12 month low of $119.17 and a 12 month high of $164.20. The firm has a market capitalization of $59,630.00, a price-to-earnings ratio of 33.74, a P/E/G ratio of 2.27 and a beta of 0.78. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business earned $1.39 earnings per share. Stryker’s revenue was up 6.1% compared to the same quarter last year. sell-side analysts anticipate that Stryker Corporation will post 6.49 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Friday, December 29th will be issued a $0.47 dividend. The ex-dividend date is Thursday, December 28th. This is a boost from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 1.19%. Stryker’s dividend payout ratio (DPR) is 40.09%.

Several equities research analysts recently weighed in on SYK shares. Wells Fargo & Co increased their price objective on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. Canaccord Genuity increased their price objective on shares of Stryker from $155.00 to $162.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Stifel Nicolaus increased their price objective on shares of Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Cowen set a $160.00 price objective on shares of Stryker and gave the stock a “buy” rating in a research note on Friday, October 6th. Finally, Royal Bank of Canada reiterated a “buy” rating and set a $155.00 price objective on shares of Stryker in a research note on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. Stryker has an average rating of “Hold” and a consensus price target of $156.60.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Stryker Corporation (SYK) Stake Raised by Liberty Capital Management Inc.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/01/16/stryker-corporation-syk-stake-raised-by-liberty-capital-management-inc.html.

Stryker Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Stock Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related stocks with our FREE daily email newsletter.